NEW YORK (GenomeWeb) — Beckman Coulter and Seegene yesterday announced after the close the market an agreement under which Seegene will manufacture reagents designed exclusively for Beckman Coulter's new Veris MDx sample-to-answer molecular diagnostics system.

Specifically, Beckman Coulter will incorporate Seegene's dual-priming oligonucleotide (DPO), tagging oligonucleotide capture and extension (TOCE), and MuDT assay chemistries into its MDx platform, Beckman Coulter CSO Richard Creager said in a statement.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

CNBC reports that Amazon invested in the startup Grail as it sees an opportunity for its cloud computing company in genomics.

Lawrence Krauss writes at Slate that science is needed for good public policy and should not be ignored.

Researchers are working on re-making the yeast genome from scratch, according to the Associated Press.

In Cell this week: functional profiling of Plasmodium genome, a self-inactivating rabies virus, and more.